Last updated on October 2019

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSIS


Brief description of study

The study aims to evaluate The effect of oral (PO) CC-90001, administered once daily (QD), compared with placebo, will be evaluated in subjects with NASH and Stage 3 fibrosis and explored in subjects with NASH and Stage 4 fibrosis.

This study is designed to assess response to treatment on measures of fibrosis and other efficacy parameters.

It will also assess dose response and overall safety.

 

Clinical Study Identifier: TX228692

Find a site near you

Start Over

IMIC, Inc.

18320 Franjo Road Palmetto Bay, FL USA
  Connect »